Skip to content Skip to footer
Subscribe Now
Viewpoints_Juan Camilo Arjona Ferreira
VIEWPOINTS

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

In an interview with PharmaShots, Myovant's Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP's positive opinion for Ryeqo (Relugolix Combination Tablet). Shots: The CHMP has adopted positive opinion recommending approval of Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of…
July 5, 2021

Read more

Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021

Read more

Viewpoints_Andrea DiFabio
VIEWPOINTS

PharmaShots Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding

In an interview with PharmaShots, Andrea DiFabio, JD, Chief Legal and Administration Officer of Repertoire Immune Medicines shares her views on the importance of $189M series B funding and how it will support the company's pipeline and manufacturing plans. Shots: The company reported the completion of a $189 million Series B financing. Founded by Flagship…
June 30, 2021

Read more

Insights+ Key Biosimilars Events of June 2021
INSIGHTS+

Insights+ Key Biosimilars Events of June 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…
June 30, 2021

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine

In an Interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific, and Medical Affairs at Medicago share her views on the P-II results of adjuvanted plant-based COVID-19 vaccine. Shots: The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged =18yrs. with two age groups (18-64yrs & over 65yrs.) across…
June 29, 2021

Read more

Viewpoints_Kevin Cammack
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Kevin Cammack Shares Insights on Lilly’s Collaboration with Global Diabetes Technology Companies

In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly and Company shares insights on the Lilly alliance with DexCom, Glooko, myDiabby Healthcare, and Roche to provide compatibility between their unique digital management platforms and Lilly's Tempo Pen and Tempo Smart Button. Shots: Eli Lilly collaborates with DexCom, Glooko, myDiabby Healthcare, and Roche to…
June 28, 2021

Read more

Viewpoints_Dr. Bina Naik and Dr. Ashish Indani
VIEWPOINTS

PharmaShots Interview: Impact of new regulations and trends in the medical device industry in India – interviews of Dr. Bina Naik and Dr. Ashish Indani during DIA Medical Device Conference 20

The Medical Devices Conference was hosted by DIA India on 21st and 22nd February in collaboration with the Medical Technology Association of India (MTaI), AIC-AMTZ Medivalley Incubation Council and mDI Europa, is one of the largest gatherings of medical devices professionals in the region. The conference was focused on giving better insights into the challenges…
June 22, 2021

Read more

Viewpoints_Thomas Slavin
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Thomas Slavin Shares Insights on the Data Validating Breast Cancer PRS Across Ancestries

In an interview with PharmaShots, Dr. Thomas Slavin, M.D, Senior Vice President of Medical Affairs, Oncology at Myriad Genetics and study co-author shared his views on the data presented at ASCO 2021 and its implications for women. Shots: Myriad Genetics data helps more women to control their health by helping them understand their lifetime risk of developing…
June 22, 2021

Read more

Viewpoints_Dr. Bob Deans
VIEWPOINTS

PharmaShots Interview: Synthego’s Dr. Bob Deans Shares Insights on the Launch of its Eclipse Platform for Drug Discovery

In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform to enhance disease modeling, drug target identification, and validation, and accelerate cell therapy manufacturing. Shots: Eclipse uses MLto apply experience from several hundred thousand genome edits across…
June 22, 2021

Read more

Viewpoints_Nan Li
VIEWPOINTS

PharmaShots Interview: Janssen’s Nan Li Shares Insights on the Data Presented at ISPOR 2021

In an interview with PharmaShots, Nan Li, Director of Access, Janssen Retina DAS shared her views on the attempts to quantify the economic burden of X-linked retinitis pigmentosa and achromatopsia. Shots: Janssen presented two posters on the economic burden and impact on people living with inherited retinal diseases X-linked retinitis pigmentosa (XLRP) and achromatopsia at ISPOR 2021…
June 21, 2021

Read more

Load more